Bringing Psychedelic Therapy into Public Health Care

Psychedelic-assisted psychotherapy is entering mainstream discourse, and the MIND Foundation is a key actor in bringing this treatment into the public health insurance system. We recently completed the world’s largest publicly funded (BMBF) clinical trial with psilocybin for depression as junior partners of ZI Mannheim and Charité Berlin. MIND is now preparing a phase-III trial that will bring psilocybin therapy to patients in a legal, safe, evidence-based, and accessible way.

A value-based scientific approach is crucial for a sustainable re-introduction of psychedelic substances, especially now in times of growing public interest.

We need to be clear about both potentials and risks of psychedelics as we take it out of a niche and into the center of society.